Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PD-L1 Negative”

145 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 145 results

Large-scale testing (Phase 3)Study completedNCT02819518
What this trial is testing

Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)

Who this might be right for
Triple Negative Breast Cancer (TNBC)
Merck Sharp & Dohme LLC 882
Large-scale testing (Phase 3)Active Not RecruitingNCT05374512
What this trial is testing

Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

Who this might be right for
Breast Cancer
AstraZeneca 644
Early research (Phase 1)Ended earlyNCT02936102
What this trial is testing

FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

Who this might be right for
Advanced Solid TumorsTriple Negative Breast CancerChordoma and Alveolar Soft Part Sarcoma
Novartis Pharmaceuticals 154
Large-scale testing (Phase 3)Study completedNCT04148911
What this trial is testing

Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer

Who this might be right for
Triple-Negative Breast Cancer
Hoffmann-La Roche 184
Testing effectiveness (Phase 2)Looking for participantsNCT07523529
What this trial is testing

Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors

Who this might be right for
Advanced UnresectableMetastatic
Beijing Biotech 72
Large-scale testing (Phase 3)Study completedNCT03125902
What this trial is testing

Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)

Who this might be right for
Triple-Negative Breast Cancer
Hoffmann-La Roche 653
Not applicableEnded earlyNCT05742269
What this trial is testing

Molecular PD-L1 PET/CT Imaging With 89Zr-atezolizumab in Metastatic Triple Negative Breast Cancer

Who this might be right for
Metastatic Triple-Negative Breast Carcinoma
Karolinska University Hospital 3
Early research (Phase 1)Study completedNCT04504669
What this trial is testing

First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours

Who this might be right for
Clear Cell Renal Cell CancerNon-Small-Cell Lung CancerTriple Negative Breast Neoplasms+6 more
AstraZeneca 60
Large-scale testing (Phase 3)Study completedNCT03036488
What this trial is testing

Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)

Who this might be right for
Triple Negative Breast Neoplasms
Merck Sharp & Dohme LLC 1,174
Very early researchStudy completedNCT03911453
What this trial is testing

Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors

Who this might be right for
Breast Cancer
University of Arizona 20
Large-scale testing (Phase 3)Study completedNCT02926196
What this trial is testing

Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab

Who this might be right for
Triple Negative Breast Neoplasms
Istituto Oncologico Veneto IRCCS 474
Early research (Phase 1)Study completedNCT03289962
What this trial is testing

Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors

Who this might be right for
MelanomaNon-Small Cell Lung CancerBladder Cancer+5 more
Genentech, Inc. 273
Testing effectiveness (Phase 2)Ended earlyNCT04442126
What this trial is testing

NM21-1480 in Adult Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorNon-small Cell Lung CancerColorectal Cancer+6 more
Numab Therapeutics AG 52
Early research (Phase 1)Study completedNCT03396445
What this trial is testing

Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001)

Who this might be right for
PharmacokineticsSolid TumorCarcinoma, Non-Small-Cell Lung+1 more
Merck Sharp & Dohme LLC 182
Large-scale testing (Phase 3)Looking for participantsNCT06103864
What this trial is testing

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

Who this might be right for
Breast Cancer
AstraZeneca 625
Large-scale testing (Phase 3)Study completedNCT02369874
What this trial is testing

Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer

Who this might be right for
Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHN
AstraZeneca 736
Not applicableStudy completedNCT03564197
What this trial is testing

18F-PD-L1 PET/CT in Nivolumab Treated Patients With NSCLC

Who this might be right for
NSCLC Stage IV
The Netherlands Cancer Institute 80
Large-scale testing (Phase 3)Study completedNCT03197935
What this trial is testing

Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer

Who this might be right for
Triple-negative Breast Cancer
Hoffmann-La Roche 333
Testing effectiveness (Phase 2)Ended earlyNCT04927884
What this trial is testing

Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies

Who this might be right for
Advanced Triple Negative Breast Cancer
ImmunityBio, Inc. 3
Not applicableNot Yet RecruitingNCT07191405
What this trial is testing

Clinical Study of Chemotherapy and Immunotherapy Combined With Lactobacillus Johnsonii in Patients With Multiple Irresectable Solid Tumors

Who this might be right for
ImmunotherapyChemotherapy
Second Affiliated Hospital, School of Medicine, Zhejiang University 156
Load More Results